3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
Meropenem
7
Vancomycin
6
pegfilgrastim
5
Filgrastim
5
Ceftazidime
5
pegylated granulocyte colony-stimulating factor
4
Cefepime
4
Levofloxacin
3
Ciprofloxacin
3
Amikacin
3
Teicoplanin
2
Piperacillin, Tazobactam Drug Combination
2
Linezolid
2
Interleukin 1 Receptor Antagonist Protein
2
Anti-Bacterial Agents
2
Amoxicillin-Potassium Clavulanate Combination
2
ceftolozane, tazobactam drug combination
1
Vaccination
1
Therapeutics
1
Tazobactam
1
TKN732
1
Surveys and Questionnaires
1
Sodium Chloride
1
Simvastatin
1
Positron Emission Tomography Computed Tomography
1
Pneumococcal Vaccines
1
Piperacillin
1
Ofloxacin
1
NF protocol
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Febrile Neutropenia
×
ceftolozane, tazobactam drug combination
×
Classical hematology
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn